Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

URL

https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v3.full-text

Authors

Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, John C. O’Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, and Venky Soundararajan

Published Date

August 21, 2021

Organization

nference

Key Excerpts

“In July, vaccine effectiveness against hospitalization has remained high (mRNA-1273: 81%, 95% CI: 33-96.3%; BNT162b2: 75%, 95% CI: 24-93.9%), but effectiveness against infection was lower for both vaccines (mRNA-1273: 76%, 95% CI: 58-87%; BNT162b2: 42%, 95% CI: 13-62%), with a more pronounced reduction for BNT162b2.”

The copyright holder for this priprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license. https://creativecommons.org/licenses/by-nd/4.0/

Medium

document

Topics

breakthrough cases,COVID-19,hospitalizations,vaccines,mRNA